High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy

Prostate

Volumn 74, Issue 5, 2014, Pages 509-519

  Haller, Andrew C ^a   Tan, Wei ^a   Payne Ondracek, Rochelle ^a   Underwood, Willie ^a   Tian, Lili ^a   Morrison, Carl ^a   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

androgen receptor; metastasis; prostate; SPDEF

Indexed keywords

ANDROGEN RECEPTOR; METASTASIS; PROSTATE; SPDEF;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84894240534     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22770     Document Type: Article

References (35)

1. Mohler JL,. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008; 617: 223-234.
2. Azzouni F, Mohler J,. Biology of castration-recurrent prostate cancer. Urol Clin North Am 2012; 39: 435-452.
3. Harris WP, Mostaghel EA, Nelson PS, Montgomery B,. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76-85.
4. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-1671.
5. Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M,. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2003; 2: 41-45. (Pubitemid 37012420)
6. Huggins C,. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942; 115: 1192-1200.
7. Ohlson N, Wikstrom P, Stattin P, Bergh A,. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 2005; 62: 307-315. (Pubitemid 40224136)
8. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM,. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009; 461: 495-500.
9. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON,. Identification of a cell of origin for human prostate cancer. Science 2010; 329: 568-571.
10. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ,. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
11. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ,. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468: 1095-1099.
12. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA,. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006; 175: 1337-1340.
13. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-4319. (Pubitemid 32685750)
14. Attar RM, Takimoto CH, Gottardis MM,. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009; 15: 3251-3255.
15. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM,. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011; 71: 1486-1496.
16. Titus MA, Zeithaml B, Kantor B, Li X, Haack K, Moore DT, Wilson EM, Mohler JL, Kafri T,. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS ONE 2012; 7: e30192.
17. Chen H, Nandi AK, Li X, Bieberich CJ,. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 2002; 62: 338-340. (Pubitemid 34106398)
18. Steffan JJ, Koul S, Meacham RB, Koul HK,. The transcription factor SPDEF suppresses prostate tumor metastasis. J Biol Chem 2012; 287: 29968-29978.
19. Noah TK, Kazanjian A, Whitsett J, Shroyer NF,. SAM pointed domain ETS factor (SPDEF) regulates terminal differentiation and maturation of intestinal goblet cells. Exp Cell Res 2010; 316: 452-465.
20. Chen G, Korfhagen TR, Xu Y, Kitzmiller J, Wert SE, Maeda Y, Gregorieff A, Clevers H, Whitsett JA,. SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. J Clin Invest 2009; 119: 2914-2924.
21. Sood AK, Kim H, Geradts J,. PDEF in prostate cancer. Prostate 2012; 72: 592-596.
22. Steffan JJ, Koul HK,. Prostate derived ETS factor (PDEF): A putative tumor metastasis suppressor. Cancer Lett 2011; 310: 109-117.
23. Turner DP, Findlay VJ, Moussa O, Semenchenko VI, Watson PM, LaRue AC, Desouki MM, Fraig M, Watson DK,. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 2011; 71: 1723-1735.
24. Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maroni PD, Meacham RB, Koul HK,. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF. Mol Cancer 2010; 9: 148.
25. Schaefer JS, Sabherwal Y, Shi HY, Sriraman V, Richards J, Minella A, Turner DP, Watson DK, Zhang M,. Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J Biol Chem 2010; 285: 11258-11269.
26. Sood AK,. PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer. Immunol Res 2010; 46: 206-215.
27. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA,. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007; 67: 4219-4226. (Pubitemid 46815068)
28. Ghadersohi A, Sharma S, Zhang S, Azrak RG, Wilding GE, Manjili MH, Li F,. Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate 2011; 71: 1178-1188.
29. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F,. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 2007; 102: 19-30.
30. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M,. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
31. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, Yan J, Talukder S, Turunen M, Taipale M, Stunnenberg HG, Ukkonen E, Hughes TR, Bulyk ML, Taipale J,. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010; 29: 2147-2160.
32. Lu S, Tan Z, Wortman M, Dong Z,. Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells. Int J Oncol 2010; 36: 459-467.
33. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ,. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997; 126: 59-73. (Pubitemid 27055548)
34. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C,. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-12187.
35. Park KS, Korfhagen TR, Bruno MD, Kitzmiller JA, Wan H, Wert SE, Khurana Hershey GK, Chen G, Whitsett JA,. SPDEF regulates goblet cell hyperplasia in the airway epithelium. J Clin Invest 2007; 117: 978-988. (Pubitemid 46556754)